Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Tibetan caraway enteric soft capsule is a botanical drug candidate developed by the Tianjin Institute of Pharmaceutical Research for the treatment of functional dyspepsia, specifically the epigastric pain syndrome (EPS) subtype. The formulation is an enteric-coated soft capsule containing a combination of essential oils, typically caraway oil (derived from *Carum carvi*) and peppermint oil. These components work synergistically to alleviate symptoms such as epigastric pain and burning by exerting antispasmodic effects on gastrointestinal smooth muscle, likely through the inhibition of L-type calcium channels, and by modulating visceral sensitivity. The enteric coating ensures that the active ingredients are released in the small intestine, minimizing gastric irritation and optimizing local therapeutic action. As of 2021, the drug was undergoing Phase 3 clinical evaluation in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on compound Tibetan caraway enteric soft capsule.